Evidence map›Paper›PMID 41617239›Full record

ArticleBMJ open2026

Cross-sectional epidemiological assessment of lymphatic filariasis situation in areas under post-mass drug administration surveillance and the associated risk of transmission in the context of migrants in India: a study protocol.

Adinarayanan Srividya, Raja J Dinesh, Muhammed Jabir M M, Manikandan Kishanthini, Vishal Dogra, Bhupendra Tripathi, Rinku Sharma, Tanu Jain, Manju Rahi

Abstract read
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adinarayanan Srividya *ICMR - Vector Control Research Centre, Puducherry, India.
Raja J Dinesh *ICMR - Vector Control Research Centre, Puducherry, India.ORCID http://orcid.org/0000-0002-3359-3039
Muhammed Jabir M M *ICMR - Vector Control Research Centre, Puducherry, India.ORCID http://orcid.org/0000-0002-4503-4867
Manikandan KishanthiniICMR - Vector Control Research Centre, Puducherry, India.
Vishal DograGates Foundation, New Delhi, India.
Bhupendra TripathiInfectious Diseases & Vaccine Delivery, Gates Foundation, New Delhi, India.
Rinku SharmaNational Center for Vector Borne Diseases Control, Government of India Ministry of Health & Family Welfare, New Delhi, India.
Tanu JainNational Center for Vector Borne Diseases Control, Government of India Ministry of Health & Family Welfare, New Delhi, India.
Manju RahiICMR - Vector Control Research Centre, Puducherry, India drmanjurahi@gmail.com.ORCID http://orcid.org/0000-0003-0932-0935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIndia targets to eliminate lymphatic filariasis (LF) in alignment with the global goals. By 2024, 106 out of a total of 345 endemic districts have passed all three serial transmission assessment surveys (TAS) and are under post-mass drug administration (MDA) surveillance for a variable period. However, the current epidemiological situation of LF is not known in these districts. With increased mobility of population from the endemic districts currently under MDA to these post-MDA areas, resurgence of LF in these areas cannot be ruled out. Therefore, a study is planned to understand the current LF status in areas under post-MDA surveillance with the following objectives: (1) To assess the epidemiological situation of LF in terms of human and vector infection prevalence in selected evaluation units (EUs) under different durations of post-MDA phase and (2) to estimate the filarial infection (in terms of filarial antigen and microfilaria) among migrants (from endemic districts) in these EUs. METHODS AND ANALYSIS: This cross-sectional study will measure the filarial infection in (1) adult population aged ≥20 years (following the WHO 2025 protocol for monitoring and evaluation of MDA) among general population (n=3150 per EU), (2) migrant population (aged 2 years and above) in the post-MDA area originating from endemic areas (n=1000 per EU) and (3) vectors (n=7500 per EU) using molecular xenomonitoring (MX) to confirm sustenance of transmission interruption or identify any potential risk of resurgence in three EUs under post-MDA phase. In one MDA-naive EU that shares borders with endemic districts, filarial infection status will be assessed in (1) school children aged 9-14 years (as per WHO mini-TAS protocol, n=480), (2) migrants (aged 2 years and above) from endemic areas (n=1000) and (3) vectors (n=7500). EU-wide prevalence of microfilaria, circulating filarial antigen and vector infection rates with 95% CIs will be estimated. Multivariate logistic regression analysis will be carried out to find factors associated with LF positivity. In addition, knowledge, attitude and practice surveys will also be conducted among the adult migrants (n=1000 per EU). Thirty in-depth interviews will be conducted among the migrants, local community and health workers (in each EU) and the results will be suitably analysed and triangulated. The study results will enable the national programme to confirm sustenance of transmission interruption or assist in taking a decision to reinitiate MDA in these areas under post-MDA surveillance. It will also enable devising specific strategies to treat migrants. ETHICS AND DISSEMINATION: This study has been approved by the institutional ethics committee (IHEC 03-0824/N/F). A workshop will be held with all stakeholders to disseminate the study findings.

Indexed as

Elephantiasis, FilarialFilaricidesMass Drug AdministrationTransients and MigrantsAdultAnimalsCross-Sectional StudiesEndemic DiseasesFemaleHumansIndiaMalePrevalenceResearch DesignRisk FactorsYoung AdultFilaricidesEPIDEMIOLOGIC STUDIESINFECTIOUS DISEASESPUBLIC HEALTHTropical medicine

Identifiers

PMID41617239
PMCPMC12863371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.